News | May 01, 2023
IOL Chemicals and Pharmaceuticals reports Q4 FY23 PAT at Rs. 65 Cr
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Specialty Chemicals grew 38% YoY for FY23
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Integration of modern and traditional medicine to facilitate the illness to wellness journey
This is especially the case if the patients are young, have multiple blocks & have conditions that may make angioplasty to implant drug-eluting stents ineffective
Spain’s renowned centre of excellence recognises importance of verifying radiosurgery plans ahead of patient treatment
Time to combine innovation, access and technology to deliver positive patient outcomes
Subscribe To Our Newsletter & Stay Updated
